Education
About Us
Working with TipRanks
Follow Us
Humacyte (HUMA)
NASDAQ:HUMA
HUMA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.81 - $9.97
Previous CloseN/A
Volume1.64M
Average Volume (3M)1.99M
Market Cap
$373.14M
Enterprise Value$646.13M
Total Cash (Recent Filing)$39.93M
Total Debt (Recent Filing)$28.86M
Price to Earnings (P/E)―
Beta1.07
Next Earnings
Mar 21, 2025EPS Estimate
-0.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.34
Shares Outstanding128,668,490
10 Day Avg. Volume2,712,992
30 Day Avg. Volume1,987,065
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.73
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-8.44
Enterprise Value/Ebitda-4.94
Forecast
1Y Price Target
$12.38Price Target Upside326.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Bulls Say, Bears Say
Bulls Say
Market AdoptionHospital reviews of Symvess already underway, with 21 hospitals having initiated their review and approval process, indicating a strong start for the product's launch.
Product LaunchHumacyte has officially launched SYMVESS, its acellular tissue-engineered vessel (ATEV), in the vascular trauma indication, marking a significant milestone for the company's first FDA-approved commercial indication.
Regulatory ApprovalThe FDA granted Humacyte full approval for Symvess use in adults as a vascular conduit for extremity arterial injury, highlighting regulatory confidence in the product.
Bears Say
---
Ownership Overview
5.94% Insiders
5.75% Mutual Funds
5.90% Other Institutional Investors
71.93% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HUMA FAQ
What was Humacyte’s price range in the past 12 months?
Humacyte lowest stock price was $2.81 and its highest was $9.97 in the past 12 months.
What is Humacyte’s market cap?
Humacyte’s market cap is $373.14M.
When is Humacyte’s upcoming earnings report date?
Humacyte’s upcoming earnings report date is Mar 21, 2025 which is in 9 days.
How were Humacyte’s earnings last quarter?
Humacyte released its earnings results on Nov 08, 2024. The company reported -$0.33 earnings per share for the quarter, missing the consensus estimate of -$0.249 by -$0.081.
Is Humacyte overvalued?
According to Wall Street analysts Humacyte’s price is currently Undervalued.
Does Humacyte pay dividends?
Humacyte does not currently pay dividends.
What is Humacyte’s EPS estimate?
Humacyte’s EPS estimate is -0.25.
How many shares outstanding does Humacyte have?
Humacyte has 128,668,490 shares outstanding.
What happened to Humacyte’s price movement after its last earnings report?
Humacyte reported an EPS of -$0.33 in its last earnings report, missing expectations of -$0.249. Following the earnings report the stock price went up 9.886%.
Which hedge fund is a major shareholder of Humacyte?
Currently, no hedge funds are holding shares in HUMA
---
Humacyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.38 (326.90% Upside)
$12.38 (326.90% Upside)
Blogger Sentiment
Bullish
HUMA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $20.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 11.4%
Last 30 Days ▼ 11.4%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-13.94%
12-Months-Change
Fundamentals
Return on Equity
239.90%
Trailing 12-Months
Asset Growth
-23.18%
Trailing 12-Months
Company Description
Humacyte
Alpha Healthcare Acquisition Corp is a blank check company.
---
HUMA Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call highlighted significant clinical advancements and strategic progress, particularly in the areas of regulatory achievements and clinical trial results. However, the delay in FDA review and increased financial losses pose notable challenges.Read More>---
HUMA Stock 12 Month Forecast
Average Price Target
$12.38
▲(326.90% Upside)
Technical Analysis
Best Analysts Covering HUMA
1 Year
1 Year Success Rate
8/22 ratings generated profit
1 Year Average Return
-8.28%
reiterated a buy rating 3 months ago
Copying Ryan Zimmerman's trades and holding each position for 1 Year would result in 36.36% of your transactions generating a profit, with an average return of -8.28% per trade.
---